My research team is focused on human parasites of major relevance to the Australian water industry and/or global public health. Our primary focus is the use of advanced technologies to improve understanding of these parasites and to utilize this information to underpin development of new drugs to treat them and novel diagnostic tests to improve their control.
Biostatistical Innovation And Capacity Building To Advance Child Health And Life-course Epidemiology
Funder
National Health and Medical Research Council
Funding Amount
$470,144.00
Summary
Biostatistics is a critical component of health and medical research. The proposed program of novel biostatistical research into methods for analysing incomplete data, an extensive portfolio of collaborative research in infant development, and establishment of a national biostatistics network, will facilitate my ongoing leadership in this critical discipline as well as enhancing the international standing of biostatistics in Australia.
Optimising Treatment As Prevention Strategies For Hepatitis C And HIV
Funder
National Health and Medical Research Council
Funding Amount
$471,809.00
Summary
New evidence shows how hepatitis C (HCV) and HIV transmission can be reduced dramatically through timely treatment initiation - treatment as prevention (TasP). TasP has re-focused attention on early HCV and HIV detection and treatment. Through observational studies, randomised control trials and the development of innovative surveillance systems, this fellowship will inform ways to maximise the potential of HCV and HIV prevention responses in Australia and internationally in this new TasP era.
The Ethics And Politics Of Pharmaceutical Innovation And Translation
Funder
National Health and Medical Research Council
Funding Amount
$476,728.00
Summary
I lead a research program on the ethics and politics of pharmaceutical innovation and translation: how medicines are developed, regulated, funded and taken up into practice. I aim to help policymakers to deal with conflicts among stakeholders. Over the next 4 years I will conduct a suite of research projects on topics of immediate significance to Australian policymakers; develop a new framework for pharmaceutical ethics and create a “Pharmaceutical Ethics and Politics Network.”